Skip to main content
Medical information Clinical review pending

Cytogenetics

FISH 17P TP53 Deletion Test

The FISH 17P TP53 Deletion Test uses Fluorescence In Situ Hybridization (FISH) to detect specific genetic abnormalities in chromosome 17, particularly the deletion of the TP53 gene. This test is important for diagnosing and managing Multiple Myeloma.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
5 mL (3 mL minimum) whole blood OR 4 mL (2 mL minimum) Bone Marrow collected in 2 Green Top (Sodium Heparin) tubes.
Results
Report available in 4 days. Sample should be received daily by 4 pm.
Preparation
A duly filled Chromosome & FISH analysis Requisition Form (Form 17) is mandatory. Confirm with the laboratory before booking.
Test priceKSh 13,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the FISH 17P TP53 Deletion Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis of Multiple Myeloma
  • ✓Prognosis assessment in Multiple Myeloma
  • ✓Guiding treatment decisions for Multiple Myeloma
  • ✓Identifying patients potentially requiring more intensive therapy
  • ✓Evaluating patients with symptoms suggestive of Multiple Myeloma
02

In plain language

What this test helps you understand

This test helps identify the deletion of the TP53 gene on chromosome 17, which is associated with Multiple Myeloma. Detecting this deletion provides important prognostic information and can guide treatment decisions, potentially indicating the need for more intensive therapies.
The FISH 17P TP53 Deletion Test is a specialized genetic test used primarily in the diagnosis and management of Multiple Myeloma, a type of blood cancer. It utilizes Fluorescence In Situ Hybridization (FISH) technology to identify specific genetic changes within cells.

This test focuses on detecting the deletion of the TP53 gene, located on chromosome 17. The presence or absence of this gene can significantly impact the prognosis and treatment strategy for Multiple Myeloma patients. Understanding these genetic alterations helps healthcare providers tailor treatment plans effectively.

This test is particularly relevant for individuals diagnosed with Multiple Myeloma or those presenting with symptoms suggestive of the condition, such as persistent fatigue, bone pain, or unexplained weight loss. It may also be considered for patients with a family history of blood cancers or those with risk factors identified by their physician.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationA duly filled Chromosome & FISH analysis Requisition Form (Form 17) is mandatory. Confirm with the laboratory before booking.
Sample5 mL (3 mL minimum) whole blood OR 4 mL (2 mL minimum) Bone Marrow collected in 2 Green Top (Sodium Heparin) tubes.
MethodologyFluorescence In Situ Hybridization (FISH)
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically detects the deletion of the TP53 gene on chromosome 17. It does not detect other genetic abnormalities. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Multiple Myeloma is a type of cancer that affects plasma cells, a type of white blood cell, in the bone marrow.
The TP53 gene is a tumor suppressor gene. Deletions or mutations in this gene can be associated with more aggressive forms of cancer, including Multiple Myeloma.
The sample is typically collected as a blood draw or a bone marrow aspiration. Your doctor will advise on the appropriate method.
A positive result indicates the presence of the TP53 deletion. This information helps your doctor understand the potential behavior of the cancer and plan the most effective treatment.
It is crucial to discuss your test results with your oncologist or healthcare provider. They can explain the implications of the findings in the context of your overall health.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp